

# Biocia Innovation Leads Eye Drop Market in 2015

*Biocia Inc. announced the recent commercialization of their viscoadaptive eye drop innovations in a preservative-free delivery system for disorders such as DED.*

PORT MURRAY, NEW JERSEY, USA, March 16, 2015 /EINPresswire.com/ -- [Biocia](#) Inc., a New Jersey-based biotechnology company announced the recent commercialization of their viscoadaptive eye drop innovations in a preservative-free delivery system through key Biocia licensing partners in North America for Ocular Surface Disorder (OSD) such as dry eye disease (DED). Biocia licensing partners include Oasis Medical Inc. in the United States ([Oasis Tears® PF](#)) and I-MED Pharma in Canada ([i-drop® Pur](#) and [i-drop® Pur GEL](#)).

Viscoadaptive eye drops are lubricant eye drop solutions which exhibit both cohesive and dispersive behaviours depending on the shear energy in the solution. At low shear rates the solution exhibits cohesive behaviour (enhanced viscosity for lubrication, protection and prevention of evaporation of the tear film) and at higher shear rates it may exhibit dispersive behaviour (enhanced elasticity for optimal patient comfort and longer residence time requiring fewer applications during the day and/or night).

Lubricant eye drops are often packaged in multi-use bottles which contain preservatives. This is not the case with this preservative-free multi-use delivery system.

Wes Domareki, MBA, Chairman of the Board, Biocia Inc. and Biocia Consulting Group commented: "i-drop® Pur, i-drop® Pur GEL and Oasis Tears® PF are the culmination of research and product development at Biocia dedicated to trends that reflect patient preference."

Ilan Hofmann, Ph.D., President of both I-MED and Biocia commented: "This latest innovation is strengthening I-MED's commercial presence in the Canadian OSD market which is projected to be growing >13% per year with state-of-the-art products that are superior to others commonly



i-drop® Pur GEL for Dry Eyes

marketed in Canada."

Craig Delgado, MBA, President of Oasis Medical Inc. commented: "We are pleased to have found a convenient delivery system for Oasis Tears® that combines the benefits of preservative-free TEARS with the convenience of an easy-to-to-use multi-use bottle."

For further information contact:

Wes Domareki at: 908 852 2311, e-mail: wesBIOCIA@aol.com

or

Ilan Hofmann at: (514) 685-8118 e-mail: info@imedpharma.com

or

Denise Starbird,

Oasis Medical Inc. at: 909 305 5414 e-mail: dstarbird@oasismedical.com

Press release courtesy of Online PR Media: <http://bit.ly/1DsJlLf>

Wes Domareki

Biocia

908 852 2311

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/255062851>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.